VHB937

Phase 2Biologic

Novartis

VHB937 is one of 44 biologic programs targeting Amyotrophic Lateral Sclerosis (ALS). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Amyotrophic Lateral Sclerosis (ALS)Active, not recruiting

Alzheimer's DiseaseRecruiting

Amyotrophic Lateral Sclerosis (ALS)Phase 2

Active, not recruiting

Alzheimer's DiseasePhase 2

Recruiting

Competition

Competitive Landscape

59 competitors in Alzheimer's Disease

#DrugCompanyPhaseTrials

Aricept

Eisai

Approved

31 2

Leqembi

Eisai

Phase 3

7 3

Nuplazid

AACADIA Pharmaceuticals Inc.

Ozempic

3 5

Qalsody

Biogen

Phase 3

1 6

Namenda

AbbVie

Phase 2

2 7

Briviact

UCB

Phase 2

1 8

Leukine

Sanofi

Phase 2

1 9

Niacor

AbbVie

Phase 2

1 10

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Active, not recruiting

Amyotrophic Lateral Sclerosis (ALS)

NCT06643481

Q4 2030

Phase 2Recruiting

Alzheimer's Disease

NCT07094516

Clinical

Trials by Indication[1]

Amyotrophic Lateral Sclerosis (ALS)1 trial

A Phase 2, Randomized, Double-blind, Placebo-controlled Parallel Group Study of VHB937 in Amyotrophic Lateral Sclerosis (ALS) Over 40 Weeks Followed by an Open Label Extension (ASTRALS)

Active, not recruiting· Novartis logo

Novartis·Phase 2·NCT06643481·251 enrolled

Alzheimer's Disease1 trial

A Randomized, Placebo-controlled, Parallel Group, 72-week Study to Evaluate the Efficacy and Safety of VHB937 in Participants With Early Alzheimer's Disease Followed by an Extension

Recruiting· Novartis logo

Novartis·Phase 2·NCT07094516·407 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for VHB937. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VHB937 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VHB937. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: Novartis

VHB937

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q4 2030

Trials by Indication[1]

Amyotrophic Lateral Sclerosis (ALS)1 trial

Alzheimer's Disease1 trial

References

Drug Info

Quick Facts

Related News